BridgeBio
BBOT
BridgeBio (BBOT) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $25.00 from $27.00 | Aug 14, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $27.00 | Jul 8, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $22.00 | Jun 22, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $23.00 | May 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $29.00 from $27.00 | Mar 6, 2026 |
| Stifel | Initiated Coverage | Buy | $23.00 | Feb 11, 2026 |
| Raymond James | Initiated Coverage | Outperform | $24.00 | Jan 9, 2026 |
| Wedbush | Maintained | Outperform | $25.00 | Dec 11, 2025 |
| Morgan Stanley | Initiated Coverage | Overweight | $20.00 | Dec 5, 2025 |
| Wedbush | Maintained | Outperform | $25.00 | Nov 25, 2025 |
| Oppenheimer | Maintained | Outperform | $22.00 from $23.00 | Nov 13, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $25.00 | Sep 17, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $27.00 | Sep 15, 2025 |
| Oppenheimer | Initiated Coverage | Outperform | $23.00 | Sep 4, 2025 |
| Wedbush | Initiated Coverage | Outperform | $25.00 | Aug 18, 2025 |
Frequently asked questions
What is the latest analyst rating on BBOT?
On Aug 14, 2026, JP Morgan maintained BridgeBio at Overweight with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.